Pegalin ER 82.5 mg (Tablet (Extended Release))

Indications

• Neuropathic pain associated with diabetic peripheral neuropathy (DPN)
• Postherpetic neuralgia (PHN)
• Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older
• Fibromyalgia
• Neuropathic pain associated with spinal cord injury

Pharmacology

• Structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA)
• Binds with high affinity to the alpha2-delta site in central nervous system tissues

Dosage

• Maximum recommended dose of 100 mg three times a day for neuropathic pain associated with diabetic peripheral neuropathy
• Recommended dose of 75 to 150 mg two times a day for postherpetic neuralgia
• Recommended dose of 300 to 450 mg/day for management of fibromyalgia
• Recommended dose range of 150 to 600 mg/day for neuropathic pain associated with spinal cord injury

Administration

• Oral route of administration
• Can be taken with or without food

Interaction

• Unlikely to be involved in significant pharmacokinetic drug interactions

Contraindications

• Contraindicated in patients with known hypersensitivity to Pregabalin or any of its components

Side Effects

• Common side effects in adults include dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, and thinking abnormal
• Common side effects in pediatric patients include increased weight and increased appetite

Pregnancy & Lactation

• No adequate and well-controlled studies in pregnant women
• Small amounts detected in the milk of lactating women
• Breastfeeding not recommended due to potential risk of tumorigenicity

Precautions & Warnings

• Angioedema can occur and may be associated with life-threatening respiratory compromise
• Discontinue immediately in case of hypersensitivity reactions
• Increase risk of suicidal thoughts or behavior
• May cause dizziness, somnolence, and impair the ability to drive or operate machinery
• Withdraw gradually over a minimum of 1 week
• May cause peripheral edema
• Caution when coadministering with thiazolidinedione antidiabetic agents

Use in Special Populations

• Safety and effectiveness in pediatric patients have not been established for various conditions

Overdose Effects

• Signs and symptoms include reduced consciousness, depression/anxiety, confusional state, agitation, and restlessness
• Seizures and heart block reported
• No specific antidote
• General supportive care indicated

Therapeutic Class

• Adjunct anti-epileptic drugs
• Primary anti-epileptic drugs

Storage Conditions

• Keep in a cool & dry place (below 30°C), protected from light & moisture
• Keep out of the reach of children

Chemical Structure

• Molecular Formula: C8H17NO2
• Chemical Structure: Image of chemical structure provided

Common Questions about Pegalin ER 82.5 mg Tablet

• What is Pegalin ER 82.5 mg XR Tablet?
• How long do I need to use Pegalin ER 82.5 mg XR Tablet before I see improvement in my condition?
• At what frequency do I need to use Pegalin ER 82.5 mg XR Tablet?
• Should I use Pegalin ER 82.5 mg XR Tablet empty stomach, before food or after food?
• What are the instructions for the storage and disposal of Pegalin ER 82.5 mg XR Tablet?
• Does Pegalin ER 82.5 mg XR Tablet work in the same way for each disease?
• How long do I need to take Pegalin ER 82.5 mg XR Tablet?
• Is it necessary to continue taking Pegalin ER 82.5 mg XR Tablet even if I feel fine?
• Can I take Diazepam and Pegalin ER 82.5 mg XR Tablet together?
• Can the use of Pegalin ER 82.5 mg XR Tablet cause weight gain?
• Quick Tips: Dosage, driving precautions, vision changes, mood and behavior changes, gradually stop taking the tablet

Related Brands

• Nervalin CR 165 mg (Tablet (Extended Release)) - beximco-pharmaceuticals-ltd
• Nervalin CR 82.5 mg (Tablet (Extended Release)) - beximco-pharmaceuticals-ltd
• Neugalin XR 165 mg (Tablet (Extended Release)) - acme-laboratories-ltd
• Neugalin XR 82.5 mg (Tablet (Extended Release)) - acme-laboratories-ltd
• Nervalin 100 mg/5 ml (Oral Solution) - beximco-pharmaceuticals-ltd